Michael Atkins
Director/Miembro de la Junta en WEREWOLF THERAPEUTICS, INC. .
Fortuna: 89 542 $ al 30/04/2024
Perfil
Michael B.
Atkins is currently the Director at the Melanoma Research Foundation.
He is also an Independent Director at Werewolf Therapeutics, Inc. starting in 2024.
Additionally, he holds the position of President at the Society For Immunotherapy of Cancer.
In 2002, he started working as a Professor at Harvard Medical School.
Dr. Atkins completed his undergraduate degree at Tufts University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 04/01/2024 | 14 419 ( 0.03% ) | 89 542 $ | 30/04/2024 |
Cargos activos de Michael Atkins
| Empresas | Cargo | Inicio |
|---|---|---|
| WEREWOLF THERAPEUTICS, INC. | Director/Miembro de la Junta | 04/01/2024 |
Melanoma Research Foundation
 Melanoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Research Foundation engages in finding treatments and cure for melanoma through research. It also educates patients, caregivers, and physicians about the prevention and diagnosis of melanoma. The company was founded by Diana Ashby in 1996 and is headquartered in Washington, DC. | Director/Miembro de la Junta | - |
| Harvard Medical School | Corporate Officer/Principal | 01/01/2002 |
Society For Immunotherapy of Cancer
 Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Presidente | - |
Formación de Michael Atkins.
| Tufts University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Melanoma Research Foundation
Melanoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Research Foundation engages in finding treatments and cure for melanoma through research. It also educates patients, caregivers, and physicians about the prevention and diagnosis of melanoma. The company was founded by Diana Ashby in 1996 and is headquartered in Washington, DC. | Commercial Services |
Society For Immunotherapy of Cancer
Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Commercial Services |
- Bolsa de valores
- Insiders
- Michael Atkins
